Symyx completes Integrity Biosolution acquisition
This article was originally published in Scrip
The US R&D integration firmSymyx Technologies has acquired the biologics formulation company Integrity Biosolution for an undisclosed cash sum. The acquisition will allow Symyx's research services division to offer both biologics and chemical formulation services, it says. In the second quarter ended June 30th, Symyx had revenues of $40.7 million and made a net loss of $1.5 million; it had a cash balance of $88 million at the end of the quarter. Symyx's technology platform includes electronic lab notebooks, software for integrating workflows and other R&D services.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.